1. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. NDM Metallo-β-Lactamases and their bacterial producers in health care settings. Clin Microbiol Rev 2019; 32(2): e00115-18.
2. Tiseo G, Suardi LR, Leonildi A, Giordano C, Barnini S, Falcone M. Meropenem/vaborbactam plus aztreonam for the treatment of New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae infections. J Antimicrob Chemother 2023; 78: 2377-2379.
3. Bianco G, Boattini M, Comini S, Casale R, Iannaccone M, Cavallo R, et al. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. Eur J Clin Microbiol Infect Dis 2022; 41: 573-580.
4. Papp-Wallace KM. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opin Pharmacother 2019; 20: 2169-2184.
5. Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 2018; 37: 1411-1419.
6. Vena A, Giacobbe DR, Castaldo N, Cattelan A, Mussini C, Luzzati R, et al. Clinical experience with Ceftazidime-Avibactam for the treatment of infections due to multidrug-resistant Gram-Negative bacteria other than carbapenem-resistant Enterobacterales. Antibiotics (Basel) 2020; 9: 71.
7. Sheu C-C, Chang Y-T, Lin S-Y, Chen Y-H, Hsueh P-R. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on Therapeutic options. Front Microbiol 2019; 10: 80.
8. Teo JQ, Fauzi N, Ho JJ, Tan SH, Lee SJ, Lim TP, et al. In vitro bactericidal activities of combination antibiotic therapies against Carbapenem-Resistant Klebsiella pneumoniae with different Carbapenemases and Sequence types. Front Microbiol 2021; 12: 779988.
9. Clinical and Laboratory Standards Institute (CLSI) (2021). Performance Standards for antimicrobial susceptibility testing. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, USA. https://www.treata.academy/wp-content/uploads/2021/03/CLSI-31-2021.pdf
10. Borgohain A, Rangaiah A, Rangappa KG. In Vitro Effect of Ceftazidime-Avibactam by synergy testing with Aztreonam using Disc E Strip Method - Contribution of Promising Combination in the Era of antibiotic resistance. Int J Pharm Clin Res 2024; 16: 1249-1255.
11. Cismaru IM, Vacaroiu MC, Soium E, Holban T, Radu AM, Melinte V, et al. Synergistic Combination of Aztreonam and Ceftazidime-Avibactam-A Promising Defense Strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania. Antibiotics (Basel) 2024; 13: 550.
12. Shaw E, Rombauts A, Tubau F, Padulles A, Camara J, Lozano T, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2018; 73: 1104-1106.
13. Niu S, Wei J, Zou C, Chavda KD, Lv J, Zhang H, et al. In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2020; 75: 559-565.
14. Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis 2017; 65: 1-3.
15. Wu Y, Yu W, Chu X, Zhang J, Jia P, Liu X, et al . Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr 2024; 12(6): e0010724.
16. Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, et al. Evaluation of the synergy of ceftazidime-avibactam in combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019; 63(8): e00779-19.
17. Wang F, Zhou Q, Yang X, Bai Y, Cui J. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment. PLoS One 2021; 16(10): e0258426.
18. Rogers TM, Kline EG, Griffith MP, Jones CE, Rubio AM, Squires KM, et al. Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae. JAC Antimicrob Resist 2023; 5: dlad113.